SUBSCRIBE FOR FREE

Your comprehensive guide

to the latest cannabis science.

Your comprehensive guide

to the latest cannabis science.

SUBSCRIBE FOR FREE

KANNAINSIGHT SCIENCE ALERTS

Your COMPREHENSIVE guide to the latest cannabinoid science

Clinical Trials

Analytical Studies

Regulatory Science

Reviews & Editorials

In Vitro Studies

Animal Studies

Safety Studies

• Receive Newly Released Science on Cannabinoids

• Review Easy-To-Understand Summaries Of Scientific Research

• Read Curated & Researched Reports On The Impact of Cannabinoids on Ailments

• Learn How to Integrate Scientific Research & Findings Into Your Brand(s) & Wellness Programs.

• Powered By Kannainsight’s Proprietary Artificial Intelligence (AI) Technology

SCIENCE

Examples of scientific research you can expect from KannAInsight are provided below:

POTENTIAL CANNABINOID TREATMENT FOR ANXIETY AND SLEEP DISORDERS

There is scientific preclinical and clinical evidence documenting the value of CBD in some neuropsychiatric disorders, including epilepsy, anxiety, and schizophrenia. Evidence points towards a calming effect for CBD in the central nervous system. This recent University of Colorado clinical study on the utilization of CBD for anxiety and sleep disorders showed promising results. Anxiety was reduced in 80% of patients in the study, and 66% of patients showed improved sleep.

CANNABINOIDS SHOW A POSITIVE INDICATION FOR CANCER THERAPY

Research into the application of cannabis and cannabinoids continues to show a wide spectrum of therapeutic potential. Studies describe CBD as a multitarget molecule with the ability to act in different ways, depending on the location in the brain and in the body. This literature review highlights recent findings on CBD’s potential for cancer treatment; from its ability to slow cancer growth, to increasing cancer cell death, to enhancing the effectiveness of anticancer drugs.

MEDICAL CANNABIS SHOWS PAIN RELIEF FOR PATIENTS WITH CHRONIC PAIN

Chronic pain is a pervasive medical condition in the US, affecting approximately 20% of US adults. Treatment of chronic pain is difficult and frequently incomplete to the patient and physician. This recent clinical trial evaluated the use of THC and cannabinoids on chronic pain and its consequences. The results were positive with patients experiencing a significant reduction in pain for 12 months following the study. Pain intensity and disability were reduced by 38% and 21%, respectively, and pain associated depression by 35%. The researchers note that while cannabis is not the answer for everyone’s pain, it is an effective tool for pain management and an intriguing supplement to traditional pain therapy.

PRICING

Subscribe today to be on the forefront of cannabinoid science across the globe!

Subscribe before March 31st, 2019 to receive 30% off ($41 / month for 1 year)

FREE-ACCESS SCIENCE

  • Up to 5 Studies Per Week
  • Featured Article of the Week With Summary
  • Special Offers
  • Access to Educational Science Programs

$41 Per Month For 1-Year

FULL-ACCESS SCIENCE

  • Up To 5 Summaries Per Week Of Critical Science
  • Average 20 Studies Per Week
  • Access to Specific Ailments Research
  • Monthly Call w/ KannAInsight Scientist or Special Guest (Starting June, 2019)
  • Access to the Kannainsight Scientific Network to Apply Studies To Your Goals

TESTIMONIALS

“KannAInsight is a game-changer for anyone who wants to grow a business in cannabis: How can you lead without understanding key data related to the science of cannabinoids?”

Kyra ReedKadin Academy, Women Entrepreneurs in Cannabis

“As an investor, we look for products and services that are authentic, transparent and on the leading edge of technology and science. Kannainsight’s weekly reports are essential reading for anyone who works with cannabinoinds.”

Brandy GrayFounder, BG Enterprises

“I am rallying my clients to know in what ways cannabinoids affect the body, if you are going to be manufacturing and selling products that “heal”.”

Zak ZaidmanBrand Launch Expert

917-699-6688

© Copyright – 2019 KannAInsight